Cannabis is no longer operating in a legal gray zone when it comes to product liability. Courts across the country are applying traditional product liability principles to THC and hemp-derived products just as they would to pharmaceuticals, alcohol, or consumer electronics.
Recent decisions make one thing clear: Regulatory compliance alone is not enough. Operators must assume that products will be scrutinized under strict liability standards. Retailers cannot assume they will be dismissed early. And hemp-derived products are now squarely in the litigation spotlight.
The good news is that courts are also applying predictable filters. When operators build defensible systems around testing, warnings, documentation, and insurance, many claims fail before reaching a jury.
Here is what the recent cases teach us.
What the Courts Are Doing
1. RICO Exposure Is Real
In Medical Marijuana, Inc. v. Horn, 604 U.S. 593 (2025), the Supreme Court of the United States held in a 5-4 decision that a plaintiff may pursue treble damages under the Racketeer Influenced and Corrupt Organizations (RICO) Act for economic losses allegedly caused by a mislabeled CBD product that, in fact, contained THC. RICO, codified at 18 U.S.C. § 1964(c), provides a private right of action for individuals injured in their business or property by reason of a RICO violation, including conduct involving a pattern of racketeering activity.
In this case, the plaintiff alleged that the manufacturer’s actions triggered the RICO statute, as the mislabeled product constituted a fraudulent scheme and concealed product risks. A successful RICO claimant is entitled to treble damages, meaning the court may award three times the amount of proven compensatory damages.
The court considered claims brought by a commercial truck driver who alleged that he consumed a product labeled THC-free, subsequently failed a drug test, and lost his job as a result. The RICO Act generally does not permit recovery for personal injury; however, the parties agreed that ingestion of the mislabeled product was a personal injury. The court held that RICO does not automatically bar recovery where a plaintiff alleges a distinct economic injury – such as lost employment – even if that economic loss flowed from the ingestion of a product.
Although the court remanded the case for further proceedings, the decision establishes binding precedent. For companies operating in the hemp-derived products market, the ruling materially increases litigation risk: Product mislabeling may now expose manufacturers and distributors to potential treble-damages liability under RICO.
2. Potency Overshoot Alone Is Not Enough
In Watt v. Trulieve Holdings Inc., No. 2025 U.S. Dist. LEXIS 230921 (D. Ariz. Aug. 28, 2025), plaintiffs alleged that edibles exceeded state potency limits and were improperly packaged. The plaintiffs further alleged that the edibles were marketed in order to deceive and confuse consumers. The plaintiffs did not allege that they suffered any physical injury or actual damages. Instead, they claimed only that they would not have purchased the products had they known they exceeded state potency limits.
On Aug. 28, 2025, the U.S. District of Arizona dismissed the case for lack of Article III standing. The court held that alleging a regulatory violation without a concrete injury-in-fact is insufficient.
The plaintiffs subsequently sought reconsideration, but as of early 2026, the dismissal remains in effect. The decision reinforces that even in the cannabis industry, federal courts continue to require plaintiffs to demonstrate a concrete injury, rather than a mere regulatory deviation, in order to maintain viable product liability or consumer protection claims.
3. Retailers Cannot Assume Early Dismissal
In Liskowitz v. 732 Vape, et al. (N.J. Super. Law Div., 2025), a consumer alleged that high-potency hemp-derived products caused cannabis-induced psychosis and a subsequent suicide attempt. Retail defendants moved to dismiss under New Jersey’s Products Liability Act, which provides that the seller of a product may be held strictly liable only if the plaintiff proves that the product was not reasonably fit, suitable, or safe for its intended purpose.
The court denied dismissal of the strict liability claims. It held that defective design, failure to warn, and proximate causation were sufficiently alleged at the pleading stage. The court refused to dismiss the retail chain based on seller immunity because discovery had not yet clarified the manufacturers’ amenability to suit, by providing both the names and addresses of the manufacturers for various products purchased by the plaintiff, and because the complaint alleged that the seller had knowledge of the products’ alleged defects, which resulted in the plaintiff’s injuries and damages.
The court dismissed the plaintiff’s Consumer Fraud Act claim against the seller, as the plaintiff failed to plead sufficient facts to show that he sustained an ascertainable loss of damages, and the standalone punitive damages count, but the core strict liability claims survived.
For operators and retailers, this case is a warning. Hemp-derived products are not insulated from strict liability exposure. Moreover, retailers may remain defendants at least through the discovery phase, where plaintiffs plausibly assert that the seller had knowledge of a product’s alleged defect or associated risks.
4. Misuse Is Often a Jury Question
In Minugh v. MiniNail, LLC, 2025 U.S. Dist. LEXIS 191529 (D. Or. Sept. 29, 2025), a federal court examined the scope of product liability for a vaporizer marketed for cannabis concentrates. The plaintiff used the device to vaporize fentanyl and later suffered severe burns after tripping over the product’s power cord. The retailer argued that the plaintiff’s injuries resulted from unforeseeable misuse, noting that the device had been used to vaporize an illegal substance multiple times per day for nearly a year.
The court granted summary judgment on warranty claims but denied summary judgment on strict liability, finding that the plaintiff’s conduct was not “patently unforeseeable.” It emphasized that product misuse is typically a question for a jury and that broad marketing language, such as describing a device simply as being “for concentrates,” could make alternative substance use foreseeable.
The court also pointed to the product’s warnings, which stated that the device “heats to extreme temperatures” and cautioned users to watch for loose cables that could be snagged. Even with these warnings, the court found it was not inherently unforeseeable that a user might place the device on the floor and ultimately trip over the cord.
Ultimately, the parties appear to have recently reached a settlement resulting in an agreement to dismiss this litigation with prejudice. However, the court’s holding concerning unforeseeable misuse of the vaporizer will remain an important precedent for hardware manufacturers and retailers when determining appropriate warnings for their products.
For hardware manufacturers, the decision highlights an important risk-management lesson: Product descriptions and intended-use statements must be carefully defined. Demonstrating that a product was used in an unintended way may not be sufficient to avoid liability. Instead, the key question may be whether that use was reasonably foreseeable to the manufacturer.
A similar, developing area of product liability litigation concerns defective vape hardware and exploding, rechargeable lithium‑ion batteries. In Simons v. Shenzhen Geekvape Technology Co. Ltd., presently pending in the U.S. District Court for the Eastern District of North Carolina (Case No. 7:25-cv-00510), the plaintiff, a consumer, alleges that a removable battery exploded in his pocket, causing severe burns. The plaintiff originally named both the Chinese manufacturer and its U.S. distributor. The distributor has since been voluntarily dismissed, and the action now focuses on the foreign manufacturer.
Although the case is presently unresolved, it underscores a common issue for vape-related claims: Injuries may stem from batteries or hardware sourced overseas and integrated into consumer devices. Courts in these cases must then confront jurisdictional questions and apportion responsibility across the distribution chain for design defects or inadequate warnings.
For cannabis operators and other retailers of vape products, the practical takeaway is clear: Disciplined hardware sourcing and thorough supply‑chain documentation are essential components of risk management.
5. Punitive Damages Require Specific Allegations
In Pena v. Sprig Patient Coop., 2021 Cal. Super. LEXIS 116258, a California trial court struck punitive damages allegations sought by the plaintiff who had suffered injury after unknowingly consuming a beverage that contained THC. The plaintiff failed to plead malice or fraud with the specificity required to support punitive damages. The plaintiff failed to state any factual allegations concerning how the facility, which sold the relevant beverage, acted to willfully permit or ignore the distribution and consumption of cannabis on its premises.
The ruling underscores an important point for cannabis operators and retailers: Courts are not lowering traditional pleading standards simply because a case involves cannabis products. To pursue punitive damages, plaintiffs must still allege, and ultimately prove, that a manufacturer or seller acted with deliberate misconduct, such as fraud or malice, in the production or distribution of the product.
6. Injury Still Matters
In Flores v. LivWell, Inc., 2016 Colo. Dist. LEXIS 1658 (Colo. Dist. Ct. Feb. 11, 2016), a Colorado court dismissed claims arising from alleged pesticide contamination in cannabis products where the plaintiffs asserted only economic harm. The plaintiffs claimed they unknowingly purchased cannabis that contained an anti-fungal agent and argued that they would not have bought or used the product had they known it contained that ingredient.
The court noted, however, that the anti-fungal agent was listed as an ingredient in the product. More importantly, the plaintiffs did not allege that they suffered any physical injury or other concrete harm from using the cannabis. Their claims were based solely on the argument that they overpaid for the product.
The court’s decision highlights that economic dissatisfaction alone is generally insufficient to establish strict product liability. To move forward with such claims, plaintiffs must show that they experienced a tangible injury from use of the cannabis-related product, rather than relying solely on allegations that they would not have purchased the product.
The Cannabis Product Liability Filter: How Courts Are Screening Claims in 2026
From these recent holdings, it is clear that in order for a cannabis product claim to succeed, it must clear five hurdles.
Stage 1: Standing
Has the plaintiff alleged a concrete injury such as economic loss or bodily harm?
If not, the case should be dismissed. It is not enough for a plaintiff to simply claim that they would not have purchased a product, had it been labeled or marketed in line with regulatory standards. Watt confirms this.
Stage 2: Causation
Can the plaintiff tie their injury to your specific product?
Proximate causation is an essential element of any product liability claim. Batch traceability and retained samples can defeat weak causation claims where a manufacturer can conclusively show that its product was not defective. Maintaining samples beyond statutory minimums can help build a strong defense to product liability claims.
Stage 3: Foreseeability
Was the product used in a way operators or retailers should have anticipated?
Broad marketing language increases risk. Minugh shows that misuse is rarely automatic dismissal; manufacturers must anticipate that consumers will use their products for unintended purposes, such as the consumption of alternative controlled substances.
Stage 4: Adequacy of Warnings
Was the risk clearly disclosed?
Prominent, specific warnings are one of the strongest shields. Manufacturers should analyze and specifically warn consumers of potential injuries, even those that could arise through unintended use of the product.
Stage 5: Damages
Are punitive or treble damages justified?
Pena shows punitive damages require specific facts. Horn shows economic injury can trigger treble damages under RICO, creating significantly increased exposure for manufacturers and retailers.
Key Takeaway
The recent cases reveal a consistent pattern: The viability of cannabis product liability claims can be largely dependent upon foreseeability, warnings, and documented compliance. Courts are not creating cannabis-specific liability rules. Instead, they are applying traditional product liability principles to this growing category of consumer products.
Most product liability cases are defeated at Stage 1 or Stage 4, where cannabis businesses can build their defenses by emphasizing clear and specific warnings on all products before product liability claims arise. The following steps can be implemented by cannabis operators now, so they are better positioned to stop weak product liability claims early in the litigation process.
10 Practical Steps Cannabis Operators Should Implement Now
- Conduct redundant potency testing. Consider a blind inter-laboratory comparison to demonstrate integrity.
- Retain batch samples beyond statutory minimums.
- Audit all certificates of analysis and maintain documented chain-of-custody records.
- Move all major warnings to the primary display panel.
- Add explicit warnings about delayed onset, mixing with alcohol, and mental health risks for high-THC products.
- Narrow marketing language. Avoid broad phrases such as “for concentrates” without defining intended substances.
- Vet hardware suppliers for ISO certifications and heavy metal testing.
- Execute written lab service agreements defining reporting standards and responsibilities.
- Review product liability policies for RICO exposure, federal illegality exclusions, and defense cost erosion.
- Maintain a written recall protocol with clear internal reporting channels.
What Insurers Are Looking For
These steps may also assist with obtaining product-liability insurance and making claims on such a policy. Underwriters are now focusing on:
• Documented testing integrity
• Clear warning protocols
• Supply chain oversight
• Recall history
• Policy alignment with federal exposure risks
Operators who can produce documentation during underwriting are far more likely to secure favorable coverage terms.
Final Thoughts
Cannabis litigation is no longer hypothetical. Courts are treating these products like any other consumer good. Strict liability claims will continue to grow, particularly in the hemp-derived market.
Operators who invest in disciplined systems, precise warnings, and robust insurance review will be positioned to stop claims early in the litigation filter.
The industry has matured. Risk management must mature with it.
